Baohui Han

机构：Shanghai Jiao Tong University, Shanghai Chest Hospital · ORCID：0000-0002-3950-3030

发表论文 686 篇 · 总被引 15226 次 · h-index 57

代表论文

• Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer (2024 · Cancer Cell · 被引 22)
• Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer (2025 · Cell Death and Disease · 被引 9)
• First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study (2025 · Journal of Thoracic Oncology · 被引 9)
• Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial (2025 · 癌症：英文版 · 被引 9)
• Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial (2024 · Cancer Biology and Medicine · 被引 6)
• WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRASG12C-mutant lung cancer (2025 · Cell Death and Disease · 被引 5)